Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Haller

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Nuclear Medicine and Biology|December 24, 2014
Investigation of the chick embryo as a potential alternative to the mouse for evaluation of radiopharmaceuticalsStephanie Haller, Simon M Ametamey, Roger Schibli, et al.
Molecular Cancer Therapeutics|September 14, 2013
177Lu-EC0800 combined with the antifolate pemetrexed: preclinical pilot study of folate receptor targeted radionuclide tumor therapyJosefine Reber, Stephanie Haller, Christopher P Leamon, et al.
Nuclear Medicine and Biology|July 12, 2015
Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathyStephanie Haller, Josefine Reber, Simone Brandt, et al.
Pharmaceuticals (Basel, Switzerland)|June 22, 2017
A Short-Term Biological Indicator for Long-Term Kidney Damage after Radionuclide Therapy in MiceGiovanni Pellegrini, Klaudia Siwowska, Stephanie Haller, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 9, 2013
Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugateCristina Müller, Josefine Reber, Stephanie Haller, et al.
Molecular Pharmaceutics|January 18, 2017
Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo PropertiesKlaudia Siwowska, Stephanie Haller, Francesca Bortoli, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|January 18, 2016
Imaging quality of (44)Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PETMaruta Bunka, Cristina Müller, Christiaan Vermeulen, et al.
Pharmaceuticals (Basel, Switzerland)|March 18, 2014
Folate receptor targeted alpha-therapy using terbium-149Cristina Müller, Josefine Reber, Stephanie Haller, et al.
EJNMMI Research|February 11, 2016
Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folateStephanie Haller, Giovanni Pellegrini, Christiaan Vermeulen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 19, 2014
Promising prospects for 44Sc-/47Sc-based theragnostics: application of 47Sc for radionuclide tumor therapy in miceCristina Müller, Maruta Bunka, Stephanie Haller, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Nuclear Medicine and Biology|December 24, 2014
Investigation of the chick embryo as a potential alternative to the mouse for evaluation of radiopharmaceuticalsStephanie Haller, Simon M Ametamey, Roger Schibli, et al.
Molecular Cancer Therapeutics|September 14, 2013
177Lu-EC0800 combined with the antifolate pemetrexed: preclinical pilot study of folate receptor targeted radionuclide tumor therapyJosefine Reber, Stephanie Haller, Christopher P Leamon, et al.
Nuclear Medicine and Biology|July 12, 2015
Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathyStephanie Haller, Josefine Reber, Simone Brandt, et al.
Pharmaceuticals (Basel, Switzerland)|June 22, 2017
A Short-Term Biological Indicator for Long-Term Kidney Damage after Radionuclide Therapy in MiceGiovanni Pellegrini, Klaudia Siwowska, Stephanie Haller, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 9, 2013
Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugateCristina Müller, Josefine Reber, Stephanie Haller, et al.
Molecular Pharmaceutics|January 18, 2017
Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the in Vitro and in Vivo PropertiesKlaudia Siwowska, Stephanie Haller, Francesca Bortoli, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|January 18, 2016
Imaging quality of (44)Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PETMaruta Bunka, Cristina Müller, Christiaan Vermeulen, et al.
Pharmaceuticals (Basel, Switzerland)|March 18, 2014
Folate receptor targeted alpha-therapy using terbium-149Cristina Müller, Josefine Reber, Stephanie Haller, et al.
EJNMMI Research|February 11, 2016
Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folateStephanie Haller, Giovanni Pellegrini, Christiaan Vermeulen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 19, 2014
Promising prospects for 44Sc-/47Sc-based theragnostics: application of 47Sc for radionuclide tumor therapy in miceCristina Müller, Maruta Bunka, Stephanie Haller, et al.
Pageof 2